FDA Adapts Drug Development Tool Procedures to Adopt Alzheimer’s Simulation Tool
This article was originally published in RPM Report
Executive Summary
FDA recently featured an Alzheimer’s Disease clinical trial simulation tool as another positive, but low-visibility, step toward improving the drug development pathway for the disease. The process for accepting the tool may be as important as the tool itself.